Type II transmembrane serine proteases as potential target for anti-influenza drug discovery

References

• Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. 2008;3:499–522.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179–186.
   PubMed Web of Science ®Google Scholar
• Smith RD, Keogh-Brown MR, Barnett T, et al. The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. BMJ. 2009;339:b4571.
   PubMed Web of Science ®Google Scholar
• Freemantle N, Shallcross LJ, Kyte D, et al. Oseltamivir: the real world data. BMJ. 2014;348:g2371.
   PubMed Web of Science ®Google Scholar
• van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med. 2010;363(14):1381–1382.
   PubMed Web of Science ®Google Scholar
• Viboud C, Simonsen L. Global mortality of 2009 pandemic influenza A H1N1. Lancet Infect Dis. 2012;12(9):651–653.
   PubMed Web of Science ®Google Scholar
• Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008;26(Suppl 4):D49–D53.
   PubMed Web of Science ®Google Scholar
• Adams MJ, Lefkowitz EJ, King AMQ, et al. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017). Arch Virol. 2017;162(8):2505–2538.
   PubMed Web of Science ®Google Scholar
• Smith GJ, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009;459(7250):1122–1125.
   PubMed Web of Science ®Google Scholar
• Wikramaratna PS, Sandeman M, Recker M, et al. The antigenic evolution of influenza: drift or thrift? Philos Trans R Soc Lond B Biol Sci. 2013;368(1614):20120200.
   PubMed Web of Science ®Google Scholar
• Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325(5937):197–201.
   PubMed Web of Science ®Google Scholar
• Perdue ML, Arnold F, Li S, et al. The future of cell culture-based influenza vaccine production. Expert Rev Vaccines. 2011;10(8):1183–1194.
   PubMed Web of Science ®Google Scholar
• Kallewaard NL, Corti D, Collins PJ, et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell. 2016;166(3):596–608.
   PubMed Web of Science ®Google Scholar
• Marjuki H, Mishin VP, Chai N, et al. Human monoclonal antibody 81.39a effectively neutralizes emerging influenza A viruses of group 1 and 2 hemagglutinins. J Virol. 2016;90(23):10446–10458.
   PubMed Web of Science ®Google Scholar
• Jang YH, Seong BL. Options and obstacles for designing a universal influenza vaccine. Viruses. 2014;6(8):3159–3180.
   PubMed Web of Science ®Google Scholar
• Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013;64:189–202.
   PubMed Web of Science ®Google Scholar
• Khurana S, Loving CL, Manischewitz J, et al. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med. 2013;5(200):200ra114.
   PubMed Web of Science ®Google Scholar
• Crowe JE Jr. Universal flu vaccines: primum non nocere. Sci Transl Med. 2013;5(200):200fs34.
   PubMed Web of Science ®Google Scholar
• Soema PC, Kompier R, Amorij J-P, et al. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251–263.
   PubMed Web of Science ®Google Scholar
• Wong S-S, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev. 2013;26(3):476–492.
   PubMed Web of Science ®Google Scholar
• Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA. 2006;295(8):891–894.
   PubMed Web of Science ®Google Scholar
• Song M-S, Marathe BM, Kumar G, et al. Unique determinants of neuraminidase inhibitor resistance among N3, N7, and N9 avian influenza viruses. J Virol. 2015;89(21):10891–10900.
   PubMed Web of Science ®Google Scholar
• Hai R, Schmolke M, Leyva-Grado VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun. 2013;4:2854.
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012;17(1 Pt B):159–173.
   PubMed Web of Science ®Google Scholar
• Shin W-J, Seong BL. Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. Expert Opin Drug Discov. 2013;8(4):411–426.
   PubMed Web of Science ®Google Scholar
• Engel DA. The influenza virus NS1 protein as a therapeutic target. Antiviral Res. 2013;99(3):409–416.
   PubMed Web of Science ®Google Scholar
• Chokki M, Yamamura S, Eguchi H, et al. Human airway trypsin-like protease increases mucin gene expression in airway epithelial cells. Am J Respir Cell Mol Biol. 2004;30(4):470–478.
   PubMed Web of Science ®Google Scholar
• Shaw ML. The host interactome of influenza virus presents new potential targets for antiviral drugs. Rev Med Virol. 2011;21(6):358–369.
   PubMed Web of Science ®Google Scholar
• Jorba N, Juarez S, Torreira E, et al. Analysis of the interaction of influenza virus polymerase complex with human cell factors. Proteomics. 2008;8(10):2077–2088.
   PubMed Web of Science ®Google Scholar
• Tafforeau L, Chantier T, Pradezynski F, et al. Generation and comprehensive analysis of an influenza virus polymerase cellular interaction network. J Virol. 2011;85(24):13010–13018.
   PubMed Web of Science ®Google Scholar
• Shapira SD, Gat-Viks I, Shum BO, et al. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell. 2009;139(7):1255–1267.
   PubMed Web of Science ®Google Scholar
• Triana-Baltzer GB, Sanders RL, Hedlund M, et al. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. J Antimicrob Chemother. 2011;66(1):15–28.
   PubMed Web of Science ®Google Scholar
• Edinger TO, Pohl MO, Stertz S. Entry of influenza A virus: host factors and antiviral targets. J Gen Virol. 2014;95(Pt 2):263–277.
   PubMed Web of Science ®Google Scholar
• Marjuki H, Mishin VP, Chesnokov AP, et al. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis. 2014;210(3):435–440.
   PubMed Web of Science ®Google Scholar
• Moss RB, Hansen C, Sanders RL, et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 2012;206(12):1844–1851.
   PubMed Web of Science ®Google Scholar
• Taubenberger JK. Influenza virus hemagglutinin cleavage into HA1, HA2: no laughing matter. Proc Natl Acad Sci U S A. 1998;95(17):9713–9715.
   PubMed Web of Science ®Google Scholar
• Grove J, Marsh M. The cell biology of receptor-mediated virus entry. J Cell Biol. 2011;195(7):1071–1082.
   PubMed Web of Science ®Google Scholar
• Bertram S, Glowacka I, Steffen I, et al. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev Med Virol. 2010;20(5):298–310.
   PubMed Web of Science ®Google Scholar
• Böttcher-Friebertshäuser E, Garten W, Matrosovich M, et al. The hemagglutinin: a determinant of pathogenicity. Curr Top Microbiol Immunol. 2014;385:3–34.
   PubMed Web of Science ®Google Scholar
• Wang S, Le TQ, Kurihara N, et al. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis. 2010;202(7):991–1001.
   PubMed Web of Science ®Google Scholar
• Klenk HD, Rott R, Orlich M, et al. Activation of influenza A viruses by trypsin treatment. Virology. 1975;68(2):426–439.
   PubMed Web of Science ®Google Scholar
• Kido H, Yokogoshi Y, Sakai K, et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem. 1992;267(19):13573–13579.
   PubMed Web of Science ®Google Scholar
• Murakami M, Towatari T, Ohuchi M, et al. Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus. Eur J Biochem. 2001;268(10):2847–2855.
   PubMedGoogle Scholar
• Hooper JD, Clements JA, Quigley JP, et al. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem. 2001;276(2):857–860.
   PubMed Web of Science ®Google Scholar
• Bugge TH, Antalis TM, Wu Q. Type II transmembrane serine proteases. J Biol Chem. 2009;284(35):23177–23181.
   PubMed Web of Science ®Google Scholar
• Yamaya M, Shimotai Y. Serine proteases and their inhibitors in human airway epithelial cells: effects on influenza virus replication and airway serine proteases and their inhibitors in human airway epithelial cells: effects on influenza virus replication and airway inflammation. Clin Microbiol. 2016;5(2).
   PubMedGoogle Scholar
• Kühn N, Bergmann S, Kösterke N, et al. The proteolytic activation of (H3N2) influenza A virus hemagglutinin is facilitated by different type II transmembrane serine proteases. J Virol. 2016;90(9):4298–4307.
   PubMed Web of Science ®Google Scholar
• Meyer D, Sielaff F, Hammami M, et al. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. Biochem J. 2013;452(2):331–343.
   PubMed Web of Science ®Google Scholar
• Okumura Y, Takahashi E, Yano M, et al. Novel type II transmembrane serine proteases, MSPL and TMPRSS13, proteolytically activate membrane fusion activity of the hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication. J Virol. 2010;84(10):5089–5096.
   PubMed Web of Science ®Google Scholar
• Böttcher-Friebertshäuser E, Freuer C, Sielaff F, et al. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J Virol. 2010;84(11):5605–5614.
   PubMed Web of Science ®Google Scholar
• Choi S-Y, Bertram S, Glowacka I, et al. Type II transmembrane serine proteases in cancer and viral infections. Trends Mol Med. 2009;15(7):303–312.
   PubMed Web of Science ®Google Scholar
• Böttcher E, Freuer C, Steinmetzer T, et al. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine. 2009;27(45):6324–6329.
   PubMed Web of Science ®Google Scholar
• Hatesuer B, Bertram S, Mehnert N, et al. Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice. PLoS Pathog. 2013;9(12):e1003774.
   PubMed Web of Science ®Google Scholar
• Hedstrom L. Serine protease mechanism and specificity. Chem Rev. 2002;102(12):4501–4524.
   PubMed Web of Science ®Google Scholar
• Dodson G, Wlodawer A. Catalytic triads and their relatives. Trends Biochem Sci. 1998;23(9):347–352.
   PubMed Web of Science ®Google Scholar
• Rawlings ND, Waller M, Barrett AJ, et al. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2014;42(Database issue):D503–D509.
   PubMed Web of Science ®Google Scholar
• Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006;6(7):541–550.
   PubMed Web of Science ®Google Scholar
• Zheng XL, Kitamoto Y, Sadler JE. Enteropeptidase, a type II transmembrane serine protease. Front Biosci (Elite Ed). 2009;1:242–249.
   PubMedGoogle Scholar
• Walsh PN, Ahmad SS. Proteases in blood clotting. Essays Biochem. 2002;38:95–111.
   PubMed Web of Science ®Google Scholar
• Le Magueresse-Battistoni B. Serine proteases and serine protease inhibitors in testicular physiology: the plasminogen activation system. Reproduction. 2007;134(6):721–729.
   PubMed Web of Science ®Google Scholar
• Murray AS, Varela FA, List K. Type II transmembrane serine proteases as potential targets for cancer therapy. Biol Chem. 2016;397(9):815–826.
   PubMed Web of Science ®Google Scholar
• List K, Bugge TH. Physiological and pathological functions of type II transmembrane serine proteases: lessons from transgenic mouse models and human disease-associated mutations. In: Edwards D, Høyer-Hansen G, Blasi F, et al., editors. The cancer degradome: proteases and cancer biology. New York (NY): Springer New York; 2008. p. 259–279.
   Google Scholar
• Kido H, Beppu Y, Sakai K, et al. Molecular basis of proteolytic activation of Sendai virus infection and the defensive compounds for infection. Biol Chem. 1997;378(3–4):255–263.
   PubMed Web of Science ®Google Scholar
• Böttcher E, Matrosovich T, Beyerle M, et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol. 2006;80(19):9896–9898.
   PubMed Web of Science ®Google Scholar
• Antalis TM, Buzza MS, Hodge KM, et al. The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. Biochem J. 2010;428(3):325–346.
   PubMed Web of Science ®Google Scholar
• Garten W, Braden C, Arendt A, et al. Influenza virus activating host proteases: identification, localization and inhibitors as potential therapeutics. Eur J Cell Biol. 2015;94(7–9):375–383.
   PubMed Web of Science ®Google Scholar
• Antalis TM, Conway GD, Peroutka RJ, et al. Membrane-anchored proteases in endothelial cell biology. Curr Opin Hematol. 2016;23(3):243–252.
   PubMed Web of Science ®Google Scholar
• Kitamoto Y, Veile RA, Donis-Keller H, et al. cDNA sequence and chromosomal localization of human enterokinase, the proteolytic activator of trypsinogen. Biochemistry. 1995;34(14):4562–4568.
   PubMed Web of Science ®Google Scholar
• Haworth JC, Gourley B, Hadorn B, et al. Malabsorption and growth failure due to intestinal enterokinase deficiency. J Pediatr. 1971;78(3):481–490.
   PubMed Web of Science ®Google Scholar
• Holzinger A, Maier EM, Bück C, et al. Mutations in the proenteropeptidase gene are the molecular cause of congenital enteropeptidase deficiency. Am J Hum Genet. 2002;70(1):20–25.
   PubMed Web of Science ®Google Scholar
• Yan W, Sheng N, Seto M, et al. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem. 1999;274(21):14926–14935.
   PubMed Web of Science ®Google Scholar
• Wang W, Liao X, Fukuda K, et al. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ Res. 2008;103(5):502–508.
   PubMed Web of Science ®Google Scholar
• Dries DL, Victor RG, Rame JE, et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation. 2005;112(16):2403–2410.
   PubMed Web of Science ®Google Scholar
• Rame JE, Tam SW, McNamara D, et al. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the genetic risk assessment in heart failure substudy. Circ Heart Fail. 2009;2(6):541–548.
   PubMed Web of Science ®Google Scholar
• Rame JE, Drazner MH, Post W, et al. Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload. Hypertension. 2007;49(4):857–864.
   PubMed Web of Science ®Google Scholar
• Yasuoka S, Ohnishi T, Kawano S, et al. Purification, characterization, and localization of a novel trypsin-like protease found in the human airway. Am J Respir Cell Mol Biol. 1997;16(3):300–308.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Masuda K, Ogawa H, et al. Cloning and characterization of the cDNA for human airway trypsin-like protease. J Biol Chem. 1998;273(19):11895–11901.
   PubMed Web of Science ®Google Scholar
• Sales KU, Hobson JP, Wagenaar-Miller R, et al. Expression and genetic loss of function analysis of the HAT/DESC cluster proteases TMPRSS11A and HAT. PLoS One. 2011;6(8):e23261.
   PubMed Web of Science ®Google Scholar
• Yoshinaga S, Nakahori Y, Yasuoka S. Fibrinogenolytic activity of a novel trypsin-like enzyme found in human airway. J Med Invest. 1998;45(1–4):77–86.
   PubMedGoogle Scholar
• Matsushima R, Takahashi A, Nakaya Y, et al. Human airway trypsin-like protease stimulates human bronchial fibroblast proliferation in a protease-activated receptor-2-dependent pathway. Am J Physiol Lung Cell Mol Physiol. 2006;290(2):L385–L395.
   PubMed Web of Science ®Google Scholar
• Kim TS, Heinlein C, Hackman RC, et al. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol. 2006;26(3):965–975.
   PubMed Web of Science ®Google Scholar
• Sakai K, Ami Y, Nakajima N, et al. TMPRSS2 independency for haemagglutinin cleavage in vivo differentiates influenza B virus from influenza A virus. Sci Rep. 2016;6:29430.
   PubMed Web of Science ®Google Scholar
• Kakisaka M, Sasaki Y, Yamada K, et al. A novel antiviral target structure involved in the RNA binding, dimerization, and nuclear export functions of the influenza A virus nucleoprotein. PLoS Pathog. 2015;11(7):e1005062.
   PubMed Web of Science ®Google Scholar
• Lejal N, Tarus B, Bouguyon E, et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother. 2013;57(5):2231–2242.
   PubMed Web of Science ®Google Scholar
• Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses. 2013;7(Suppl 1):63–75.
   PubMed Web of Science ®Google Scholar
• Naesens L, Stevaert A, Vanderlinden E. Antiviral therapies on the horizon for influenza. Curr Opin Pharmacol. 2016;30:106–115.
   PubMed Web of Science ®Google Scholar
• Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014;14(7):609–618.
   PubMed Web of Science ®Google Scholar
• Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem. 2009;284(43):29798–29808.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446–454.
   PubMed Web of Science ®Google Scholar
• Byrn RA, Jones SM, Bennett HB, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015;59(3):1569–1582.
   PubMed Web of Science ®Google Scholar
• Kao RY, Yang D, Lau L-S, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28(6):600–605.
   PubMed Web of Science ®Google Scholar
• Pang B, Cheung NN, Zhang W, et al. Structural characterization of H1N1 nucleoprotein-nucleozin binding sites. Sci Rep. 2016;6:29684.
   PubMed Web of Science ®Google Scholar
• Gerritz SW, Cianci C, Kim S, et al. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A. 2011;108(37):15366–15371.
   PubMed Web of Science ®Google Scholar
• Barré O, Dufour A, Eckhard U, et al. Cleavage specificity analysis of six type II transmembrane serine proteases (TTSPs) using PICS with proteome-derived peptide libraries. PLoS One. 2014;9(9):e105984.
   PubMed Web of Science ®Google Scholar
• Szabo R, Bugge TH. Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu Rev Cell Dev Biol. 2011;27:213–235.
   PubMed Web of Science ®Google Scholar
• Ohler A, Becker-Pauly C. TMPRSS4 is a type II transmembrane serine protease involved in cancer and viral infections. Biol Chem. 2012;393(9):907–914.
   PubMed Web of Science ®Google Scholar
• Chan JC, Knudson O, Wu F, et al. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A. 2005;102(3):785–790.
   PubMed Web of Science ®Google Scholar
• Zhirnov OP, Ikizler MR, Wright PF. Cleavage of influenza a virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases. J Virol. 2002;76(17):8682–8689.
   PubMed Web of Science ®Google Scholar
• Steinhauer DA. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology. 1999;258(1):1–20.
   PubMed Web of Science ®Google Scholar
• Lu X, Shi Y, Gao F, et al. Insights into avian influenza virus pathogenicity: the hemagglutinin precursor HA0 of subtype H16 has an alpha-helix structure in its cleavage site with inefficient HA1/HA2 cleavage. J Virol. 2012;86(23):12861–12870.
   PubMed Web of Science ®Google Scholar
• Chen J, Lee KH, Steinhauer DA, et al. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell. 1998;95(3):409–417.
   PubMed Web of Science ®Google Scholar
• Evnin LB, Vasquez JR, Craik CS. Substrate specificity of trypsin investigated by using a genetic selection. Proc Natl Acad Sci U S A. 1990;87(17):6659–6663.
   PubMed Web of Science ®Google Scholar
• Lazarowitz SG, Choppin PW. Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology. 1975;68(2):440–454.
   PubMed Web of Science ®Google Scholar
• Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006;311(5761):656–659.
   PubMed Web of Science ®Google Scholar
• Blouse GE, Bøtkjær KA, Deryugina E, et al. A novel mode of intervention with serine protease activity: targeting zymogen activation. J Biol Chem. 2009;284(7):4647–4657.
   PubMed Web of Science ®Google Scholar
• Hamilton BS, Whittaker GR. Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12. J Biol Chem. 2013;288(24):17399–17407.
   PubMed Web of Science ®Google Scholar
• Chaipan C, Kobasa D, Bertram S, et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J Virol. 2009;83(7):3200–3211.
   PubMed Web of Science ®Google Scholar
• Hamilton BS, Gludish DW, Whittaker GR. Cleavage activation of the human-adapted influenza virus subtypes by matriptase reveals both subtype and strain specificities. J Virol. 2012;86(19):10579–10586.
   PubMed Web of Science ®Google Scholar
• Zhirnov OP, Ovcharenko AV, Bukrinskaya AG. Myxovirus replication in chicken embryos can be suppressed by aprotinin due to the blockage of viral glycoprotein cleavage. J Gen Virol. 1985;66(7):1633–1638.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Zhou J, To KK, et al. Identification of TMPRSS2 as a susceptibility gene for severe 2009 pandemic A(H1N1) influenza and A(H7N9) influenza. J Infect Dis. 2015;212(8):1214–1221.
   PubMed Web of Science ®Google Scholar
• Stieneke-Gröber A, Vey M, Angliker H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. Embo J. 1992;11(7):2407–2414.
   PubMed Web of Science ®Google Scholar
• Suguitan AL Jr, Matsuoka Y, Lau Y-F, et al. The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals. J Virol. 2012;86(5):2706–2714.
   PubMed Web of Science ®Google Scholar
• Horimoto T, Nakayama K, Smeekens SP, et al. Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses. J Virol. 1994;68(9):6074–6078.
   PubMed Web of Science ®Google Scholar
• Kido H, Okumura Y. Mspl/Tmprss13. Front Biosci. 2008;13:754–758.
   PubMed Web of Science ®Google Scholar
• Baron J, Tarnow C, Mayoli-Nüssle D, et al. Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses. J Virol. 2013;87(3):1811–1820.
   PubMed Web of Science ®Google Scholar
• Zhirnov OP, Ovcharenko AV, Bukrinskaya AG. Protective effect of protease inhibitors in influenza virus infected animals. Arch Virol. 1982;73(3–4):263–272.
   PubMed Web of Science ®Google Scholar
• Zhirnov OP, Ovcharenko AV, Bukrinskaya AG. Suppression of influenza virus replication in infected mice by protease inhibitors. J Gen Virol. 1984;65(1):191–196.
   PubMed Web of Science ®Google Scholar
• Bahgat MM, Błazejewska P, Schughart K. Inhibition of lung serine proteases in mice: a potentially new approach to control influenza infection. Virol J. 2011;8:27.
   PubMed Web of Science ®Google Scholar
• Lee MG, Kim KH, Park KY, et al. Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses. Arch Virol. 1996;141(10):1979–1989.
   PubMed Web of Science ®Google Scholar
• Hosoya M, Shigeta S, Ishii T, et al. Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo. J Infect Dis. 1993;168(3):641–646.
   PubMed Web of Science ®Google Scholar
• Wysocka M, Spichalska B, Lesner A, et al. Substrate specificity and inhibitory study of human airway trypsin-like protease. Bioorg Med Chem. 2010;18(15):5504–5509.
   PubMed Web of Science ®Google Scholar
• Zmora P, Blazejewska P, Moldenhauer A-S, et al. DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry. J Virol. 2014;88(20):12087–12097.
   PubMed Web of Science ®Google Scholar
• Garten W, Stieneke A, Shaw E, et al. Inhibition of proteolytic activation of influenza virus hemagglutinin by specific peptidyl chloroalkyl ketones. Virology. 1989;172(1):25–31.
   PubMed Web of Science ®Google Scholar
• Beppu Y, Imamura Y, Tashiro M, et al. Human mucus protease inhibitor in airway fluids is a potential defensive compound against infection with influenza A and Sendai viruses. J Bioch. 1997;121(2):309–316.
   PubMed Web of Science ®Google Scholar
• Kyrieleis OJ, Huber R, Ong E, et al. Crystal structure of the catalytic domain of DESC1, a new member of the type II transmembrane serine proteinase family. Febs J. 2007;274(8):2148–2160.
   PubMed Web of Science ®Google Scholar
• Sielaff F, Böttcher-Friebertshäuser E, Meyer D, et al. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg Med Chem Lett. 2011;21(16):4860–4864.
   PubMed Web of Science ®Google Scholar
• Sisay MT, Steinmetzer T, Stirnberg M, et al. Identification of the first low-molecular-weight inhibitors of matriptase-2. J Med Chem. 2010;53(15):5523–5535.
   PubMed Web of Science ®Google Scholar
• Hellstern P, Stürzebecher U, Wuchold B, et al. Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin. J Thromb Haemost. 2007;5(10):2119–2126.
   PubMed Web of Science ®Google Scholar
• Böttcher-Friebertshäuser E, Lu Y, Meyer D, et al. Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections. Vaccine. 2012;30(51):7374–7380.
   PubMed Web of Science ®Google Scholar
• Yamaya M, Shimotai Y, Hatachi Y, et al. The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells. Pulm Pharmacol Ther. 2015;33:66–74.
   PubMed Web of Science ®Google Scholar
• Buzza MS, Johnson TA, Conway GD, et al. Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis. J Biol Chem. 2017;292(26):10801–10812.
   PubMed Web of Science ®Google Scholar
• Kaplan BS, Russier M, Jeevan T, et al. Novel highly pathogenic avian A(H5N2) and A(H5N8) influenza viruses of clade 2.3.4.4 from North America have limited capacity for replication and transmission in mammals. mSphere. 2016;1(2).
   PubMed Web of Science ®Google Scholar
• Zhirnov OP, Matrosovich TY, Matrosovich MN, et al. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir Chem Chemother. 2011;21(4):169–174.
   PubMedGoogle Scholar
• Zhirnov OP, Kirzhner LS, Ovcharenko AV, et al. [Clinical effectiveness of aprotinin aerosol in influenza and parainfluenza]. Vestnik Rossiiskoi akademii meditsinskikh nauk/Rossiiskaia akademiia meditsinskikh nauk. 1996;(5):26–31.
   Google Scholar
• Simmons G, Zmora P, Gierer S, et al. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res. 2013;100(3):605–614.
   PubMed Web of Science ®Google Scholar
• Krzyzaniak MA, Zumstein MT, Gerez JA, et al. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013;9(4):e1003309.
   PubMed Web of Science ®Google Scholar
• Shirato K, Kawase M, Matsuyama S. Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552–12561.
   PubMed Web of Science ®Google Scholar
• Sanjuán R, Nebot MR, Chirico N, et al. Viral mutation rates. J Virol. 2010;84(19):9733–9748.
   PubMed Web of Science ®Google Scholar
• Phougat N, Khatri S, Singh A, et al. Combination therapy: the propitious rationale for drug development. Comb Chem High Throughput Screen. 2014;17(1):53–67.
   PubMed Web of Science ®Google Scholar
• Johnson LB, Saravolatz LD. The quad pill, a once-daily combination therapy for HIV infection. Clin Infect Dis. 2014;58(1):93–98.
   PubMed Web of Science ®Google Scholar
• Steinmetzer T, Schweinitz A, Stürzebecher A, et al. Secondary amides of sulfonylated 3-amidinophenylalanine. new potent and selective inhibitors of matriptase. J Med Chem. 2006;49(14):4116–4126.
   PubMed Web of Science ®Google Scholar